#ImmunoOnc
LightNews LightNews
vjhemonc.bsky.social
🎥 Asya Varshavsky-Yanovsky shares insight into a study showing that a high peak in absolute lymphocyte count following cilta-cel infusion in patients with #myeloma predicts for increased risk of delayed neurological toxicities:

👉 buff.ly/MjL0Oku 👈

#CARTcell #MMSM #MultipleMyeloma #ImmunoOnc #IMS25
November 7, 2025 at 10:01 AM
vjhemonc.bsky.social
We had a great time interviewing leading #Myeloma experts & researchers at the 5th Oxford Myeloma Workshop last week!😁🩸

Don't forget to check out our coverage of the event here:
👉 https://buff.ly/40ISfms

Stay tuned for more soon!

#MMSM #MultipleMyeloma #HemOnc #ImmunoOnc #BloodSky #HemeSky
February 5, 2025 at 2:00 PM
vjhemonc.bsky.social
#ASH24 | It was great to interview Vaishali Sanchorawala, who presented the updated results of the ANDROMEDA trial of dara + CyBorD vs CyBorD alone in AL #Amyloidosis.

Watch here:
👉 https://buff.ly/4glJhBr 👈

#HemOnc #ImmunoOnc #CTSM #TrialUpdate @ash.hematology.org
February 1, 2025 at 5:00 PM
mtmdphd.bsky.social
Multiple Myeloma IgG Level & Pneumococcal Vaccination Ab Response [Aug 10, 2017] @mtmdphd et al. @JPCRR ow.ly/I4tn30ejvTc #mmsm #ImmunoOnc #IDonc
March 3, 2025 at 11:12 AM
vjhemonc.bsky.social
Could novel CELMoDs potentially improve anti-BCMA CAR-T functionality?

We discussed this with Samir Parekh at the Oxford Myeloma Workshop.🩸

Watch here:
🎥 buff.ly/awR9Otd

#MMSM #MultipleMyeloma #ImmunoOnc #CARTCell
March 14, 2025 at 11:00 AM
vjhemonc.bsky.social
Are in vivo genome editing methods for targeting T-cells the future of CAR-T?🧬

What are some of their benefits, and what challenges remain?

Hear from Dr William Nyberg in a recent interview from #CART25:

🎥 buff.ly/E146kjE

#ImmunoOnc #HemOnc #CARTCell #BloodSky
March 15, 2025 at 1:00 PM
vjhemonc.bsky.social
Watch our recent interview with Jae Park of @mskcancercenter.bsky.social to hear about the long-term data with obe-cel in ALL & its potential to serve as a standalone treatment for adult R/R B-ALL.

Click here:

👉 buff.ly/inx0gbp

#ALLsm #Leusm #Leukemia #CTSM #CARTCell #ImmunoOnc #HemOnc
August 1, 2025 at 4:42 PM
vjhemonc.bsky.social
#CART25 | Christian Chabannon shares updates on ongoing projects of the #GoCARTcoalition!

Click here to watch the interview:
👉 buff.ly/4hSG1Po 👈

#ImmunoOnc #HemOnc #CARTCell #Hematology #MedSky #BloodSky #HemeSky
February 25, 2025 at 1:46 PM
vjhemonc.bsky.social
What is the current role of T-cell engagers and CARs in myeloid malignancies?🩸

Find out by watching our exclusive expert discussion from #iwCART25 with David Sallman, Marion Subklewe, Jae Park, & Andrew Kuykendall here:

👉 buff.ly/mQBv32R

#AMLsm #Leusm #MPNsm #ImmunoOnc #HemeSky #BloodSky
May 15, 2025 at 3:04 PM
vjoncology.bsky.social
🎥 Xiaoqian Nie, PhD, reports Phase I data:

➡️Erythrocyte–antibody conjugates show stronger antitumor activity & better safety vs PD-1 antibodies in checkpoint-refractory cancers. Promising novel IO strategy

🔗 buff.ly/cD7UDXr

@ascocancer.bsky.social #ASCO25 #Oncology #ImmunoOnc #CTSM #TrialUpdate
Evaluating erythrocyte-antibody conjugates in solid tumors - VJOncology
Xiaoqian Nie, PhD, Westlake University, Hangzhou, China, shares results of a Phase I trial (NCT06026605) investigating erythrocyte-antibody conjugates in cancers...
buff.ly
September 14, 2025 at 8:01 AM
vjhemonc.bsky.social
At #ASH24, Kai Rejeski shared insights into CAR-Tography, a large international study that mapped CAR-T toxicities across B-cell malignancies, including CRS, ICANS, hematotoxicity, and infections.

Watch here:
👉 https://buff.ly/4gZa3Aq

#CARTCell #ImmunoOnc #HemeOnc @ash-hematology.bsky.social
January 9, 2025 at 5:00 PM
vjhemonc.bsky.social
#18ICML | Neil Berinstein of @sunnybrookhsc.bsky.social shares updates from the BRAWM trial, which is evaluating the combination of bendamustine, rituximab, & acalabrutinib in Waldenström’s macroglobulinemia:

🎥 buff.ly/svYBGt2

#LYMsm #Lymphoma #RareDisease #HemOnc #ImmunoOnc #CTSM #TrialUpdate
August 7, 2025 at 9:01 AM
vjhemonc.bsky.social
In an interview from #ASH24, Sabina Chiaretti comments on the efficacy and tolerability of frontline ponatinib + blinatumomab for adult patients with Ph+ ALL, which was studied in the GIMEMA ALL2820 trial:

👉 https://buff.ly/3WPn0VD

#ALLsm #Leusm #CTSM #HemOnc #ImmunoOnc @ash.hematology.org
February 12, 2025 at 11:04 AM
cancer-vaccine.activitypub.awakari.com.ap.brid.gy
Phase I study of B440, a WT1 cancer vaccine, in patients with metastatic urothelial cancer Margaret Gatti-Mays, MD MPH, The Ohio State University, Columbus, OH, discusses findings from a Phase I st...

#General #Medicine #News #ASCO25,UroOnc,UroSoMe,ImmunoOnc […]

[Original post on mashupmd.com]
Original post on mashupmd.com
www.mashupmd.com
June 11, 2025 at 8:41 AM
vjhemonc.bsky.social
Want to find out about the latest advances in #CARTCell therapy?🩸💉

Register for the upcoming EHA-EBMT European CAR-T Meeting, and stay tuned for our coverage of this fantastic event!🎥😁

Click here to register:
👉 https://buff.ly/49NBVVB

#CART25 #ImmunoOnc #MedSky #BloodSky #HemeSky #HemeOnc
January 13, 2025 at 2:00 PM
vjhemonc.bsky.social
Hear updates from the BP41072 trial investigating glofitamab plus englumafusp alfa in R/R B-NHL from Martin Hutchings.🩸

Click here:
👉https://buff.ly/4fGhMSJ

#LYMsm #ASH24 #NonHodgkinLymphoma #ImmunoOnc #TrialUpdate #CTSM @ash-hematology.bsky.social #Hematology #BloodSky #HemeSky #HemeOnc
January 4, 2025 at 10:00 AM
vjhemonc.bsky.social
🎥 In an interesting interview at #CART25, Andrea Kuhnl provided insight into CAR-T outcomes in patients with LBCL in the UK according to ethnicity and socioeconomic deprivation.

Watch here:
👉 buff.ly/3KHC04h 👈

#LYMsm #DLBCL #ImmunoOnc #HemOnc
March 6, 2025 at 11:00 AM
vjhemonc.bsky.social
We've had so many fantastic conversations at #EBMT25 already, and we have a whole day of interviews left to go!😁

Missed out on the meeting? Not to worry!
We'll be sharing exclusive updates with you on 👉 VJHemOnc.com 👈

#BMTsm #ImmunoOnc #HemOnc #Hematology #MedSky #BloodSky #HemeSky
April 1, 2025 at 6:30 AM
vjhemonc.bsky.social
Watch our interview from #EHA2025 with Shambavi Richard of @TischCancer to hear findings from the ongoing Phase I/IIa trial investigating HDP-101, a novel BCMA-targeting antibody-drug conjugate, in #MultipleMyeloma:

🎥 buff.ly/QdLRjUe

#MMSM #Myeloma #CTSM #ImmunoOnc #BloodSky #HemeSky #MedSky
July 22, 2025 at 7:01 AM
vjoncology.bsky.social
🎥Prof. Grant McArthur from Peter Mac (@petermaccc.bsky.social) highlights how targeted therapy reshapes the immune microenvironment in melanoma, impacting response to IO. Smarter sequencing is key!

Learn more here➡️https://buff.ly/huymybh

#Melanoma2025 #EADO2025 #Melsm #Skcsm #ImmunoOnc
Cross-resistance between targeted therapies and immune checkpoint inhibitors in melanoma - VJOncology
Grant McArthur, MBBS, FRACP, PhD, FAHMS, Peter MacCallum Cancer Centre, Melbourne, Australia, discusses the importance of understanding the interaction between...
ow.ly
April 24, 2025 at 8:02 AM
vjhemonc.bsky.social
The trial of INCA33989, a mutCALR-specific monoclonal antibody, in #EssentialThrombocythemia generated plenty of excitement at the #EHA2025 meeting last week!🩸

Hear the details from John Mascarenhas:

👉 buff.ly/DyV3HNd 👈

#MPNsm #TrialUpdate #CTSM #BloodSky #HemeSky #ImmunoOnc #MedSky
June 17, 2025 at 4:02 PM
vjhemonc.bsky.social
GPRC5D-directed therapies are reshaping the #MultipleMyeloma treatment landscape.🩸

Explore practical considerations with the use of GPRC5D-directed agents in our interactive expert feature. 🔍

Click here:
📖 buff.ly/PKlan0C

#MMsm #Myeloma #CellTherapy #ImmunoOnc #GPRC5D #HemOnc #BloodSky
August 4, 2025 at 2:02 PM
vjhemonc.bsky.social
#iwAL25 | John DiPersio comments on the challenges of treating T-cell malignancies with bispecific antibody therapy, and shares insights into the development of WU-CART-007, an anti-CD7 allogeneic CAR T-cell product:

🎥 buff.ly/s2zXiCa

#ALLsm #Leusm #ImmunoOnc #HemOnc #BloodSky #HemeSky #MedSky
October 29, 2025 at 5:42 PM
mtmdphd.bsky.social
Overestimation of tumor mutational burden (TMB) using algorithms compared to germline subtraction [May 26, 2019] @kaushalpar et al. @AMansfieldMD #ASCO19 Abstract 2621 ascopubs.org/doi/abs/10.1... #PrecisionMedicine #ImmunoOnc #geneticcounselors @MayoCancerCare @TempusLabs
May 17, 2025 at 9:34 PM
mtmdphd.bsky.social
ImmunoDriver-1: Driver alterations (dAlts) and their immunological implications in early and metastatic non-small cell lung cancer (NSCLC) - Lee et al. @UCLAHealth @TempusAI #ASCO25 Abst 8060
meetings.asco.org/abstracts-pr... #lcsm #ImmunoOnc #PrecisionMedicine
May 22, 2025 at 11:59 PM